Market Place
Sourcing Support
Clover Shares Positive Data for RSV Vaccine Candidate SCB-1019
28 Oct 2024 //
PR NEWSWIRE
Clover Announces +ve Ph I Results for SCB-1019 in Initial Young Adult Cohort
08 Apr 2024 //
PR NEWSWIRE
Clover Initiates Phase 1 Clinical Trial for RSV Vaccine Candidate
12 Dec 2023 //
PR NEWSWIRE
Clover Launches Quadrivalent Seasonal Influenza Vaccine in Mainland China
11 Sep 2023 //
GLOBENEWSWIRE
Clover Provides Updates on Business and R&D Pipeline Development
10 Jul 2023 //
GLOBENEWSWIRE
Clover Expands Sales and Distribution Network for Influenza Vaccine Launc
23 May 2023 //
GLOBENEWSWIRE
Clover Announces Corporate Updates and Full Year 2022 Financial Results
28 Mar 2023 //
GLOBENEWSWIRE
Clover Health to Present at Citi`s 2023 Healthcare Conference on March 1, 2023
22 Feb 2023 //
GLOBENEWSWIRE
Clover Enters into Agreement for Quadrivalent Seasonal Influenza Vaccine
19 Feb 2023 //
GLOBENEWSWIRE
Coronavirus (COVID-19) Current Therapy Global Market Report 2023
14 Feb 2023 //
PR NEWSWIRE
Clover Launches COVID-19 Booster Vaccine in the People’s Republic of China
14 Feb 2023 //
GLOBENEWSWIRE
Clover Launches COVID-19 Booster Vaccine in the People’s Republic of China
13 Feb 2023 //
GLOBENEWSWIRE
Clover Provides Updates on COVID-19 Vaccine Commercial Launch in 2023
15 Jan 2023 //
GLOBENEWSWIRE
Clover’s Vaccine Candidate Reduced Household Transmission of SARS-CoV-2
29 Nov 2022 //
GLOBENEWSWIRE
Clover Provides Update on 2022 Corporate Milestones
10 Oct 2022 //
GLOBENEWSWIRE
Clover touts PIII omicron data as wait for COVID-19 vaccine approvals drags on
21 Sep 2022 //
FIERCEBIOTECH
Clover’s COVID-19 Vaccine Candidate Receives European Union GMP Certificate
20 Sep 2022 //
GLOBENEWSWIRE
Clover’s Universal COVID-19 Booster Vaccine Candidate Demonstrates Superior
19 Sep 2022 //
GLOBENEWSWIRE
Clover`s COVID vaccine shows efficacy against Omicron BA.5 in trial
30 Aug 2022 //
BIOSPACE
Clover reports positive results from phase 2/3 trial of SCB-2019 in adolescents
27 Aug 2022 //
PHARMABIZ
Clover Announces Positive Phase 2/3 Results for its COVID-19 Vaccine
25 Aug 2022 //
GLOBENEWSWIRE
Clover Announces Executive Leadership Appointments
30 Jun 2022 //
GLOBENEWSWIRE
Clover says its COVID booster shot candidate lifts antibody against Omicron
28 Jun 2022 //
REUTERS
Clover Appoints Donna Ambrosino and Ralf Clemens to Board of Directors
19 Jun 2022 //
GLOBENEWSWIRE
Clover Begins Dosing with SCB-219M in PI Trial for Thrombocytopenia
14 Jun 2022 //
GLOBENEWSWIRE
Clover Begins Dosing in PIII Trial of SCB-2019 as Heterologous COVID-19 Booster
13 Jun 2022 //
GLOBENEWSWIRE
Clover to Participate in Credit Suisse Asia Healthcare Corporate Day
07 Jun 2022 //
GLOBENEWSWIRE
Clover Provides Update on 2022 Corporate Milestones
05 Jun 2022 //
GLOBENEWSWIRE
Clover Doses First Participants in PI Trial with SCB-2020S
31 May 2022 //
GLOBENEWSWIRE
Clover to Participate in Morgan Stanley Virtual China Summit 2022
17 May 2022 //
GLOBENEWSWIRE
Clover Health Reports First Quarter 2022 Financial Results
09 May 2022 //
GLOBENEWSWIRE
Clover`s Bivalent COVID-19 Vaccine Candidate Demonstrates Broad Neutralization
05 May 2022 //
GLOBENEWSWIRE
Clover Appoints LiongHo Chua as President of Greater China
27 Apr 2022 //
GLOBENEWSWIRE
Clover Presents Durability and Booster Data for COVID-19 Vaccine Candidate
19 Apr 2022 //
GLOBENEWSWIRE
Clover To Present at World Vaccine Congress Washington 2022
12 Apr 2022 //
GLOBENEWSWIRE
Clover Reports Full Year 2021 Financial Results
29 Mar 2022 //
GLOBENEWSWIRE
Clover`s COVID-19 Vaccine Candidate Demonstrates Durable High Protection
17 Mar 2022 //
GLOBENEWSWIRE
Clover`s COVID-19 Vaccine Candidate Demonstrates Durable High Protection
17 Mar 2022 //
GLOBENEWSWIRE
MALACHITE INNOVATIONS SIGNED LOI WITH RANGE ENVIRONMENTAL RESOURCES
15 Mar 2022 //
GLOBENEWSWIRE
Clover Health to Present at Barclays 2022 Global Healthcare Conference
08 Mar 2022 //
GLOBENEWSWIRE
Clover to Participate at Upcoming Investor Conferences
02 Mar 2022 //
GLOBENEWSWIRE
Clover Selected for Inclusion on the Hang Seng Composite Index
24 Feb 2022 //
GLOBENEWSWIRE
Clover Appoints Nicholas Jackson as President of Global R&D
01 Feb 2022 //
GLOBENEWSWIRE
Clover’s Final SPECTRA Phase 2/3 Trial Efficacy Data Is Published in The Lancet
20 Jan 2022 //
GLOBENEWSWIRE
Clover Biopharma sets up new R&D center in a buzzy Chinese hub near Shanghai
05 Jan 2022 //
ENDPTS
Clover Biopharmaceuticals Announces Construction of New R&D Center in Shanghai
05 Jan 2022 //
ASIAONE
Clover and Ascentage Pharma Announce Clinical Collab to Evaluate
09 Dec 2021 //
GLOBENEWSWIRE
Clover Signs COVID-19 Vaccine Supply Agreement with UNICEF
07 Dec 2021 //
GLOBENEWSWIRE
Clover’s COVID-19 Vaccine Administered as Heterologous Booster in Phase 2 Trial
26 Nov 2021 //
GLOBENEWSWIRE
Clover and CEPI Expand Partnership for COVID-19 Vaccine Candidate
18 Nov 2021 //
GLOBENEWSWIRE
Clover`s COVID-19 vaccine tames delta in pivotal study
23 Sep 2021 //
REUTERS
Chinese drugmaker Clover says vaccine prevents COVID-19 in large trial
22 Sep 2021 //
BIOPHARMADIVE
Clover`s COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta
22 Sep 2021 //
PRNEWSWIRE
China`s Clover Biopharma to launch protein-based COVID-19 vaccine by 2021-end
13 Sep 2021 //
BIOSPECTRUM ASIA
Clover Gets Manufacturing Permit from Zhejiang Medical Products Administration
09 Sep 2021 //
BIOSPACE
COVAX vaccine 2021 delivery target cut to 1.425 billion doses
08 Sep 2021 //
REUTERS
Clover to Report Second Quarter 2021 Financial Results on August 11, 2021
21 Jul 2021 //
GLOBENEWSWIRE
Clover Biopharma completes enrollment in SPECTRA phase 2/3 trial of SCB-2019
07 Jul 2021 //
PHARMABIZ
Clover Biopharmaceuticals Completes Enrollment in SPECTRA Global Phase 2/3 Trial
06 Jul 2021 //
PR NEWSWIRE
Clover, Dynavax Ink Commercial Supply Agreement of Dynavax`s CpG 1018 Adjuvant
30 Jun 2021 //
PR NEWSWIRE
